84 filings
6-K
CMMB
Chemomab Therapeutics Ltd
7 Mar 24
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results
7:00am
6-K
CMMB
Chemomab Therapeutics Ltd
3 Jan 24
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary
7:00am
6-K
CMMB
Chemomab Therapeutics Ltd
9 Nov 23
Current report (foreign)
8:00am
6-K
CMMB
Chemomab Therapeutics Ltd
14 Aug 23
Current report (foreign)
8:05am
6-K
CMMB
Chemomab Therapeutics Ltd
8 Aug 23
Current report (foreign)
6:00am
6-K
sqyo0 u4u5n1epj
3 Jul 23
Current report (foreign)
3:49pm
8-K
hteev3orjs49kgd28e
16 Jun 23
Departure of Directors or Certain Officers
4:01pm
8-K
8sz9d7yr6m6
5 Jun 23
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
7:00am
8-K
yqjawy81e5pvm
11 May 23
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
6:10am
8-K
97os syz8
21 Feb 23
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
7:05am
8-K
gxrx8l1hfcm
21 Feb 23
Results of Operations and Financial Condition
6:10am
8-K
ktig8wj 9oo8o
11 Jan 23
Regulation FD Disclosure
4:01pm
8-K
dm9ynkr 0ig
3 Jan 23
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis
7:05am
8-K/A
vg9t6dqgumisd
29 Nov 22
Financial Statements and Exhibits
6:02am
8-K
te76t
16 Nov 22
Other Events
7:21am
8-K
81mfhzx
14 Nov 22
Chemomab Announces Appointment of Matthew Frankel, MD, MBA
4:06pm
8-K
4thg59de3 hwgaqu
12 Aug 22
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
7:08am
8-K
ieb191nm a6
21 Jun 22
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
7:00am
8-K
m3y7u
8 Jun 22
Submission of Matters to a Vote of Security Holders
6:01am
8-K
nguk41vw zv02ife
1 Jun 22
Departure of Directors or Certain Officers
4:04pm